EA201590868A1 - Противовирусные соединения - Google Patents

Противовирусные соединения

Info

Publication number
EA201590868A1
EA201590868A1 EA201590868A EA201590868A EA201590868A1 EA 201590868 A1 EA201590868 A1 EA 201590868A1 EA 201590868 A EA201590868 A EA 201590868A EA 201590868 A EA201590868 A EA 201590868A EA 201590868 A1 EA201590868 A1 EA 201590868A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
virus compounds
virus
methods
introduction
Prior art date
Application number
EA201590868A
Other languages
English (en)
Other versions
EA027828B1 (ru
Inventor
Элизабет М. Бейкон
Джероми Дж. Коттелл
Джон О. Линк
Тереза Алехандра Трехо Мартин
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50974893&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590868(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201590868A1 publication Critical patent/EA201590868A1/ru
Publication of EA027828B1 publication Critical patent/EA027828B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Описание относится к противовирусным соединениям, композициям, содержащим такие соединения, и терапевтическим способам, которые включают введение таких соединений, а также к способам и промежуточным соединениям, подходящим для получения таких соединений.
EA201590868A 2012-12-21 2013-12-19 Противовирусные соединения EA027828B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745452P 2012-12-21 2012-12-21
US13/830,346 US9233974B2 (en) 2012-12-21 2013-03-14 Antiviral compounds
PCT/US2013/076734 WO2014100500A1 (en) 2012-12-21 2013-12-19 Antiviral compounds

Publications (2)

Publication Number Publication Date
EA201590868A1 true EA201590868A1 (ru) 2015-11-30
EA027828B1 EA027828B1 (ru) 2017-09-29

Family

ID=50974893

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590868A EA027828B1 (ru) 2012-12-21 2013-12-19 Противовирусные соединения
EA201790781A EA201790781A3 (ru) 2012-12-21 2013-12-19 Противовирусные соединения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790781A EA201790781A3 (ru) 2012-12-21 2013-12-19 Противовирусные соединения

Country Status (28)

Country Link
US (5) US9233974B2 (ru)
EP (3) EP2935279B1 (ru)
JP (1) JP6333849B2 (ru)
KR (2) KR20200118903A (ru)
CN (2) CN104918943B (ru)
AP (1) AP2015008511A0 (ru)
AR (1) AR094262A1 (ru)
AU (1) AU2013361195B2 (ru)
BR (1) BR112015014333A8 (ru)
CA (1) CA2893963C (ru)
CL (1) CL2015001702A1 (ru)
CR (1) CR20150370A (ru)
EA (2) EA027828B1 (ru)
ES (1) ES2626392T3 (ru)
HK (3) HK1214594A1 (ru)
IL (1) IL239496A0 (ru)
MA (1) MA38261A1 (ru)
MD (1) MD20150062A2 (ru)
MX (1) MX2015007888A (ru)
PE (1) PE20151423A1 (ru)
PH (1) PH12015501354A1 (ru)
PL (1) PL2935279T3 (ru)
PT (1) PT2935279T (ru)
SG (1) SG11201504746PA (ru)
SI (1) SI2935279T1 (ru)
TW (2) TW201835087A (ru)
UY (1) UY35241A (ru)
WO (1) WO2014100500A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101835474B1 (ko) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
PE20171444A1 (es) 2011-11-16 2017-09-29 Gilead Pharmasset Llc Compuestos antivirales
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP3421482A1 (en) 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9398640B2 (en) 2012-12-21 2016-07-19 Halliburton Energy Services, Inc. Digital multi-use thermo-cup
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
ES2714048T3 (es) 2014-09-12 2019-05-24 Janssen Pharmaceutica Nv Moduladores de P2X7
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
KR102202984B1 (ko) 2016-05-27 2021-01-13 길리애드 사이언시즈, 인코포레이티드 Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
TW201919649A (zh) * 2017-09-21 2019-06-01 美商里伯賽恩斯有限責任公司 作為ｈｃｖ ｒｎａ複製抑制劑之經４′－氟－２′－甲基取代之核苷衍生物
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
EP3856179A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica N.V. Monoacylglycerol lipase modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
WO2022246109A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AR050174A1 (es) 2004-07-16 2006-10-04 Gilead Sciences Inc Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101835474B1 (ko) * 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Also Published As

Publication number Publication date
WO2014100500A1 (en) 2014-06-26
AU2013361195B2 (en) 2018-05-17
CA2893963A1 (en) 2014-06-26
HK1216177A1 (zh) 2016-10-21
PE20151423A1 (es) 2015-10-17
EP2935279A1 (en) 2015-10-28
BR112015014333A8 (pt) 2019-10-15
EP2935279B1 (en) 2017-03-15
SI2935279T1 (sl) 2017-06-30
ES2626392T3 (es) 2017-07-24
PH12015501354A1 (en) 2015-09-07
JP2016503800A (ja) 2016-02-08
HK1214594A1 (zh) 2016-07-29
EP3239152A1 (en) 2017-11-01
SG11201504746PA (en) 2015-07-30
UY35241A (es) 2014-07-31
CN104918943A (zh) 2015-09-16
US20140178336A1 (en) 2014-06-26
CL2015001702A1 (es) 2015-08-07
AU2013361195A1 (en) 2015-06-11
US20180244684A1 (en) 2018-08-30
EA027828B1 (ru) 2017-09-29
TW201835087A (zh) 2018-10-01
KR20200118903A (ko) 2020-10-16
MX2015007888A (es) 2015-09-29
US9233974B2 (en) 2016-01-12
EA201790781A3 (ru) 2017-11-30
US20160362416A1 (en) 2016-12-15
AR094262A1 (es) 2015-07-22
PL2935279T3 (pl) 2017-08-31
TWI613202B (zh) 2018-02-01
AP2015008511A0 (en) 2015-06-30
US20160083395A1 (en) 2016-03-24
US20170369502A1 (en) 2017-12-28
BR112015014333A2 (pt) 2017-07-11
MA38261A1 (fr) 2017-06-30
IL239496A0 (en) 2015-08-31
HK1245263A1 (zh) 2018-08-24
TW201441229A (zh) 2014-11-01
KR102164390B1 (ko) 2020-10-12
KR20150100728A (ko) 2015-09-02
CR20150370A (es) 2015-08-14
JP6333849B2 (ja) 2018-05-30
CN107011350A (zh) 2017-08-04
CN104918943B (zh) 2017-04-05
EA201790781A2 (ru) 2017-08-31
PT2935279T (pt) 2017-06-02
CA2893963C (en) 2021-09-07
EP3404030A1 (en) 2018-11-21
MD20150062A2 (ru) 2015-12-31

Similar Documents

Publication Publication Date Title
EA201590868A1 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA201790963A1 (ru) Противовирусные соединения
EA201190259A1 (ru) Противовирусные соединения
EA201490132A1 (ru) Противовирусные соединения
EA200971074A1 (ru) Антивирусные соединения
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591166A1 (ru) Ингибиторы аутотаксина
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201590887A1 (ru) Композиция
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201490037A1 (ru) Антагонисты trpv4
EA201691141A1 (ru) Соединения против ccr6
EA201790570A1 (ru) Модуляторы р2х7
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201590892A1 (ru) Производные n-(пиридин-2-ил)пиримидин-4-амина, содержащие сульфоксиминовую группу
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU